SCHEMBL204078

SCHEMBL204078

O=C(c1ccc(B(O)O)cc1)N1CCCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.70
ALDH1A1 P00352 3/20 0.70
MAPK1 P28482 1/20 0.58
MLYCD O95822 2/20 0.56
LMNA P02545 1/20 0.56
MEN1 O00255 1/20 0.54
TSHR P16473 1/20 0.54
KMT2A Q03164 1/20 0.54
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA7 P43166 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53
L3MBTL1 Q9Y468 4/20 0.51
L3MBTL3 Q96JM7 3/20 0.51
USP2 O75604 1/20 0.51
MBTD1 Q05BQ5 1/20 0.51
TP53BP1 Q12888 1/20 0.51
L3MBTL4 Q8NA19 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL258027 0.98 HPGD (0.74) HPGDALDH1A1MAPK1MLYCDLMNA
SCHEMBL950365 0.96 HPGD (0.64) HPGDALDH1A1MAPK1MLYCDLMNA
SCHEMBL29950978 0.92 HPGD (0.57) HPGDALDH1A1MAPK1LMNAMEN1
SCHEMBL28890427 0.90 HPGD (0.58) HPGDALDH1A1MAPK1MLYCDLMNA
SCHEMBL10721733 0.85 HPGD (0.95) HPGDALDH1A1MAPK1MLYCDLMNA
SCHEMBL109091 0.84 PHGDH (0.65) HPGDALDH1A1MAPK1MLYCDTSHR
SCHEMBL29956781 0.84 HPGD (0.65) HPGDALDH1A1MAPK1MLYCDLMNA
SCHEMBL532147 0.84 POLB (0.65) HPGDLMNAMEN1TSHRKMT2A
SCHEMBL1951522 0.84 SIGMAR1 (0.64) HPGDALDH1A1L3MBTL1L3MBTL3
SCHEMBL1490905 0.84 HPGD (0.48) HPGDALDH1A1MAPK1MLYCDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
WO-2022159439-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2022-07-28 WO claimed
EP-2718265-B1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES AKEBIA THERAPEUTICS INC (US) 2015-12-16 EP claimed
EP-2940009-A1 METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES VentiRx Pharmaceuticals, Inc. (US) 2015-11-04 EP claimed
US-9145366-B2 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides AKEBIA THERAPEUTICS, INC. (US) 2015-09-29 US claimed
EP-2358683-B1 METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES VENTIRX PHARMACEUTICALS INC (US) 2015-04-01 EP claimed
EP-2718265-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES Akebia Therapeutics Inc. (US) 2014-04-16 EP claimed
WO-2012170377-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES AKEBIA THERAPEUTICS INC. (US) 2012-12-13 WO claimed
US-20120309977-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES AKEBIA THERAPEUTICS INC. (US) 2012-12-06 US claimed
US-8314090-B2 Methods of synthesis of benzazepine derivatives VENTIRX PHARMACEUTICALS, INC. (US) 2012-11-20 US claimed
EP-2358683-A1 METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES Ventirx Pharmaceuticals, Inc. (US) 2011-08-24 EP claimed
US-20100216989-A1 METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES VENTIRX PHARMACEUTICALS, INC. (US) 2010-08-26 US claimed
WO-2010054215-A1 METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES VENTIRX PHARMACEUTICALS, INC. (US) 2010-05-14 WO claimed
EP-4306529-B1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2026-01-21 EP disclosed
US-12522605-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2026-01-13 US disclosed
US-20060019959-A1 Novel quinoxalinone derivatives BANYU PHARMACEUTICAL CO., LTD. TSUKUBA RESEARCH INSTITUTE (JP) 2006-01-26 US disclosed
WO-2006001754-A1 NEW DERIVATIVES OF 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OR 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIC ACID ASTRAZENECA AB (SE) 2006-01-05 WO disclosed
EP-1557418-A1 NOVEL QUINOXALINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216989-A1 METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES MAOB, GABBR1, HNMT HPGD 2138/4885ALDH1A1 536/4885MAPK1 4102/4885
US-20120309977-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES HPD, APEH, ALDH7A1 HPGD 41/4885ALDH1A1 36/4885MAPK1 3424/4885
US-20060019959-A1 Novel quinoxalinone derivatives NDUFB1, NDUFB6, NDUFB11 HPGD 201/4885ALDH1A1 1279/4885MAPK1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.